ArticleNPJ vaccines2024
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.
Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- Exploration of immune phenotypes in self-sampling citizens.iScience · 2026Article
- The Role of Anti-Interferon-α Autoantibodies in Severe COVID-19: Implications for Vaccination Prioritization.Vaccines · 2025Article
- Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination.NPJ vaccines · 2025Article
- Risk factors, clinical presentations, and common culprits in drug allergies: a case-control study from Türkiye.Postepy dermatologii i alergologii · 2025Article
- Autoantibodies to protein S may explain rare cases of coagulopathy following COVID-19 vaccination.Scientific reports · 2024Article
- Challenges in the Application of African Swine Fever Vaccines in Asia.Animals : an open access journal from MDPI · 2024Article
- Article
- Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Funding
Abstract
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.